ATAI Life Sciences

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ASPN

ATAI

FSLY

LION

LPRO

PEGA

RDDT

Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

AppLovin Corp APP

AVGR

BROS

CEVA

HOOD

MGOL

MYNA

NKGN

OMGA

PRPH

SLSR

TIVC

TWIN

Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

Artificial-Intelligence-Photo-by-PopTika copy

Cannabis

Psychedelics

CMPS

DELCF

MNMD

AI and psychedelic medicine are merging, with research showing AI&#39;s role in drug discovery, trials, and personalized mental health care.

AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?

ATAI Life Sciences NV

Earnings

Press Releases

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Management

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Health Care

atai Life Sciences Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

Financing

atai Life Sciences Announces Proposed Public Offering of Common Shares

atai Life Sciences Announces Pricing of Public Offering of Common Shares

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

HC Wainwright & Co.

Canaccord Genuity

Maxim Group

EF Hutton

Credit Suisse

Screenshot 2024-05-21 at 6.46.56 PM

Biotech

General

SILO

FTRP

Revolutionizing Mental Healthcare With The Rise Of Ketamine And Psychedelic Therapies

Comments

ATAI Life Sciences

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga